# A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

> **NCT00630851** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 249 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Donepezil (Aricept)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00630851
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630851, "A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00630851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*